okyo pharma corp - OKYO

OKYO

Close Chg Chg %
2.06 -0.03 -1.46%

Pre-Market

2.03

-0.03 (1.46%)

Volume: 21.42K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: okyo pharma corp - OKYO

OKYO Key Data

Open

$2.04

Day Range

2.01 - 2.13

52 Week Range

0.90 - 3.35

Market Cap

N/A

Shares Outstanding

NaN

Public Float

22.47M

Beta

-0.03

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

144.21K

 

OKYO Performance

1 Week
 
0.00%
 
1 Month
 
3.57%
 
3 Months
 
-6.88%
 
1 Year
 
75.00%
 
5 Years
 
N/A
 

OKYO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About okyo pharma corp - OKYO

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO At a Glance

OKYO Pharma Ltd.
107 Cheapside
London, Greater London EC2V 6DN
Phone 44-20-7495-2379 Revenue 0.00
Industry Biotechnology Net Income -4,706,292.00
Sector Health Technology Employees N/A
Fiscal Year-end 03 / 2026
View SEC Filings

OKYO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.761
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

OKYO Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

OKYO Liquidity

Current Ratio 0.398
Quick Ratio 0.398
Cash Ratio 0.169

OKYO Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -180.366
Return on Equity N/A
Return on Total Capital 84.805
Return on Invested Capital N/A

OKYO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Okyo Pharma Corp - OKYO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
2.42K 3.80K 3.87K 2.56K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.42K 3.80K 3.87K 2.56K
Depreciation
2.42K 3.80K 3.87K 2.56K
Amortization of Intangibles
- - - -
-
COGS Growth
-81.49% +56.71% +1.82% -33.70%
Gross Income
(2.42K) (3.80K) (3.87K) (2.56K)
Gross Income Growth
+81.49% -56.71% -1.82% +33.70%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
6.23M 13.08M 15.69M 7.19M
Research & Development
1.30M 6.34M 8.24M 2.25M
Other SG&A
4.93M 6.75M 7.45M 4.93M
SGA Growth
+67.71% +110.04% +19.93% -54.20%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(6.23M) (13.09M) (15.69M) (7.19M)
Non Operating Income/Expense
13.58K (99.93K) (55.18K) 102.45K
Non-Operating Interest Income
- - - 5.47K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 96.69K 1.05M 883.65K
Interest Expense Growth
- - +989.40% -16.11%
-
Gross Interest Expense
- 96.69K 1.05M 883.65K
Interest Capitalized
- - - -
-
Pretax Income
(6.22M) (13.28M) (16.80M) (7.97M)
Pretax Income Growth
-57.84% -113.64% -26.49% +52.57%
Pretax Margin
- - - -
-
Income Tax
(786.55K) (12.20K) 22.42K (3.26M)
Income Tax - Current - Domestic
- (786.55K) 22.42K (3.26M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.43M) (13.27M) (16.83M) (4.71M)
Minority Interest Expense
- - - -
-
Net Income
(5.43M) (13.27M) (16.83M) (4.71M)
Net Income Growth
-38.76% -144.36% -26.78% +72.03%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.43M) (13.27M) (16.83M) (4.71M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.43M) (13.27M) (16.83M) (4.71M)
EPS (Basic)
-0.0055 -0.5963 -0.5734 -0.1192
EPS (Basic) Growth
+5.17% -10,741.82% +3.84% +79.21%
Basic Shares Outstanding
979.21M 22.26M 29.34M 39.49M
EPS (Diluted)
-0.0055 -0.5963 -0.5734 -0.1192
EPS (Diluted) Growth
+5.17% -10,741.82% +3.84% +79.21%
Diluted Shares Outstanding
979.21M 22.26M 29.34M 39.49M
EBITDA
(6.23M) (13.08M) (15.69M) (7.19M)
EBITDA Growth
-67.71% -110.04% -19.93% +54.20%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 6.00
Number of Ratings 3 Current Quarters Estimate -0.05
FY Report Date 12 / 2025 Current Year's Estimate -0.213
Last Quarter’s Earnings -0.02 Median PE on CY Estimate N/A
Year Ago Earnings -0.12 Next Fiscal Year Estimate -0.34
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 3 1
Mean Estimate -0.05 -0.08 -0.21 -0.34
High Estimates -0.05 -0.08 -0.18 -0.34
Low Estimate -0.05 -0.08 -0.27 -0.34
Coefficient of Variance N/A N/A -23.12 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 1 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Okyo Pharma Corp in the News